Different patterns of activation markers expression and CD4+ T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS)

Journal of Neuroimmunology

Volumn 189, Issue 1-2, 2007, Pages 137-146

  Kosmaczewska, A ^a   Bilinska, M ^b   Ciszak, L ^a   Noga, L ^b   Pawlak, E ^a   Szteblich, A ^a   Podemski, R ^b   Frydecka, I ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Activated CD4+ T cells; CTLA 4; IFN gamma; Multiple sclerosis; Remission; sCTLA 4

Indexed keywords

GAMMA INTERFERON;

ADULT; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL MEMBRANE; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; REMISSION;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE II; IONOMYCIN; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 34548475105     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.06.021     Document Type: Article

References (63)

1. Adachi K., Kumamoto T., and Shukuro A. Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. Ann. Neurol. 28 (1990) 687-691
2. Allison J.P. CD28-B7 interactions in T-cell activation. Curr. Opin. Immunol. 6 (1994) 414-419
3. Antel J.P., Bania M.B., Reder A., and Cashman N. Activated suppressor cell dysfunction in progressive multiple sclerosis. J. Immunol. 137 (1986) 137-141
4. Bartik M.M., Welker D., and Kay N.E. Impairment of immune cell function in B cell chronic lymphocytic leukemia. Semin. Oncol. 25 (1998) 27-33
5. Carreno B.M., Bennett F., Chau T.A., Luxenberg D., Jussif J., Baroja M.L., and Madrenas J. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J. Immunol. 165 (2000) 1352-1356
6. Castle B.E., Kishimoto K., Stearns C., Brown M., and Kehry M.R. Regulation of expression of the ligand for CD40 on T helper lymphocytes. J. Immunol. 151 (1993) 1777-1788
7. Correale J., McMillan M., McCarthy K., Lee T., and Weiner L.P. Isolation and characterization of autoreactive proteolipid protein-peptide specific T-cell clones from multiple sclerosis patients. Neurology 45 (1995) 1370-1378
8. Farahat N., van der Plas D., Praxedes M., Morilla R., Matutes E., and Catovsky D. Demonstration of cytoplasmic and nuclear antigens in acute leukemia using flow cytometry. J. Clin. Pathol. 47 (1994) 843-849
9. Filion L.G., Matusevicius D., Graziani-Bowering G.M., Kumar A., and Freedman M.S. Monocyte-derived IL-12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis. Clin. Immunol. 106 (2003) 127-138
10. Frydecka I., Kaczmarek P., Bocko D., Kosmaczewska A., Morilla R., and Catovsky D. Expression of signal-transducing zeta chain in peripheral blood T cells and natural killer cells in patients with Hodgkin's disease in different phases of the disease. Leuk. Lymphoma 35 (1999) 545-554
11. Gallo P., Piccino M.G., Pagni S., Argentiero V., Giometto B., Bozza F., and Tavolato B. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid. J. Neurol. Sci. 92 (1989) 9-15
12. Gallo P., Piccino M.G., Tavolato B., and Siden A. A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-gamma in multiple sclerosis CSF and serum. J. Neurol. Sci. 101 (1991) 227-232
13. Gerritse K., Laman J.D., Noelle R.J., Aruffo A., Ledbetter J.A., Boersma W.J.A., and Claasen E. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2499-2504
14. Grewal I.S., and Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16 (1998) 111-135
15. Hafler D.A., Buchsbaum M., and Weiner H.L. Decreased autologous mixed lymphocyte reaction in multiple sclerosis. J. Neuroimmunol. 9 (1985) 339-347
16. Huang W.X., Huang P., and Hillert J. Systemic upregulation of CD40 and CD40 ligand mRNA expression in multiple sclerosis. Mult. Scler. 6 (2000) 61-65
17. Hurwitz A.A., Sullivan T.J., Krummel M.F., Sobel R.A., and Allison J.P. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J. Neuroimmunol. 73 (1997) 57-62
18. Issazadeh S., Navikas V., Schaub M., Sayegh M., and Khoury S. Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo. J. Immunol. 161 (1998) 1104-1112
19. Jensen J., Krakauer M., and Sellebjerg F. Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis. Eur. J. Neurol. 8 (2001) 321-328
20. Kerlero de Rosbo N., Milo R., Lees M.B., Burger D., Bernard C.C.A., and Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis. J. Clin. Invest. 92 (1993) 2602-2608
21. Killestein J., Hintzen R.Q., Uitdehaag B.M.J., Baars P.A., Roos M.T., van Lier R.A.W., and Polman C.H. Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta. J. Neuroimmunol. 133 (2002) 217-224
22. Koshy M., Berger D., and Crow M. Increased expression of CD40L on systemic lupus erythematosus lymphocytes. J. Clin. Invest. 98 (1996) 826-837
23. Kosmaczewska A., Ciszak L., Bocko D., and Frydecka I. Expression and functional significance of CTLA-4, a negative regulator of T cell activation. Arch. Immunol. Ther. Exp. 49 (2001) 39-46
24. Kosmaczewska A., Frydecka I., Bocko D., Ciszak L., and Teodorowska R. Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production. Br. J. Haematol. 118 (2002) 202-209
25. Krummel M.F., and Allison J.P. CD28 and CTLA-4 have an opposite effects on response of T cell to stimulation. J. Exp. Med. 182 (1995) 459-465
26. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
27. Lee K.M., Chuang E., Griffin M., Khattri R., Hong D.K., Zhang W., Straus D., Samelson L.E., Thompson C.B., and Bluestone J.A. Molecular basis of T cell inactivation by CTLA-4. Science 282 (1998) 2263-2266
28. Leungh H.T., Bradshaw J., Cleaveland J.S., and Linsley P.S. Cytotoxic T lymphocyte-associated molecule-4, a high avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. J. Biol. Chem. 270 (1995) 1-8
29. Lindsten T., Lee K.P., Harris E.S., Petryniak B., Craighead N., Reynolds P.J., Lombard D.B., Freeman G.J., Nadler L.M., Gray G.S., Thompson C.B., and June C.H. Characterization of CTLA-4 structure and expression on human T-cells. J. Immunol. 151 (1993) 3489-3499
30. Linsley P.S., Bradshaw J., Greene J., Peach R., Benet K.L., and Mitller R.S. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4 (1996) 535-543
31. Liu M.F., Liu H.S., Wang C.R., and Lei H.Y. Expression of CTLA-4 molecule in peripheral blood T lymphocytes from patients with systemic lupus erythemotosus. J. Clin. Immunol. 18 (1998) 392-398
32. Liu M.F., Wang C.R., Chen P.C., and Fung L.L. Increased expression of soluble cytotoxic T lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand. J. Immunol. 57 (2003) 568-572
33. Liu M.F., Yang C.Y., Li J.S., Lai K.A., Chao S.C., and Lei H.Y. Increased expression of down-regulatory CTLA-4 molecule on T lymphocytes from rheimatoid synovial compartment. Scand. J. Immunol. 50 (1999) 68-72
34. Lovett-Racke A.E., Trotter J.L., Lauber J., Perrin P.J., June C.H., and Racke M.K. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. J. Clin. Invest. 101 (1998) 725-730
35. Lublin F.D., and Reigold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46 (1996) 907-911
36. MacDonald K.P.A., Nishioka Y., Lipsky P.E., and Thomas R. Functional CD40L is expressed by T cells in rheumatoid arthritis. J. Clin. Invest. 100 (1997) 2404-2414
37. Magistrelli G., Jeannin P., Herbault N., Benoit de Coignac A., Gauchat J.F., Bonnefoy J.Y., and Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 29 (1999) 3596-3602
38. Mena E., and Rohovsky-Kochan C. Expression of costimulatory molecules on peripheral blood mononuclear cells in multiple sclerosis. Acta Neurol. Scand. 100 (1999) 92-96
39. Metzler B., Burkhart C., and Wraith D.C. Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo. Int. Immunol. 11 (1999) 667-675
40. Noronha A., Toscas A., and Jensen M.A. Interferon-beta decreases T cell activation and interferon-gamma production in multiple sclerosis. J. Neuroimmunol. 46 (1993) 145-153
41. Oaks M.K., Hallet K.M., Penwell R.T., Stauber E.C., Warren S.J., and Tector A.J. A native soluble form of CTLA-4. Cell. Immunol. 201 (2000) 144-153
42. Oaks M.K., and Hallett K.M. A soluble form of CTLA-4 in patients with autoimmune thyroid disease. J. Immunol. 164 (2000) 5015-5018
43. Oliveira E.M.L., Bar-Or A., Waliszewska A.I., Cai G., Anderson D.E., Krieger J.I., and Hafler D.A. CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls. J. Autoimmun. 20 (2003) 71-82
44. Pawlak E., Kochanowska I., Frydecka I., and Bilinska M. The soluble CTLA-receptor: a new humoral marker in autoimmune diseases. Arch. Immunol. Ther. Exp. 53 (2005) 336-341
45. Perrin P.J., Maldonado J.H., Davis T.A., June C.H., and Racke M.K. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157 (1996) 1333-1336
46. Perry V.H., Wolley S.T., and Anthony D.C. The role of axonal pathology in MS disability. Int. MS J. 6 (1999) 7-13
47. Pettinelli C.B., and McFarlin D.E. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for lyt 2-T lymphocytes. J. Immunol. 127 (1981) 1420-1423
48. Poser Ch.M. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-231
49. Raine C.S. The Dale E. McFarlin Memorial lecture: the immunology of multiple sclerosis lesions. Ann. Neurol. 36 (1994) S61-S72
50. Reder A.T., Arnason B.G., Maimone D., and Rohwer-Nutter D. The function of the CD2 protein is abnormal in multiple sclerosis. J. Autoimmun. 4 (1991) 479-491
51. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., Le Page E., Edan G., McDonell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sorensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sa M., Salemi G., Savettieri G., Hillert J., and Compston D.A. Multiple Sclerosis Severity Score. Using disability and disease duration to rate disease severity. Neurology 64 (2005) 1144-1151
52. Rudick R.A., Carpenter C.S., Cookfair D.L., Tuohy V.K., and Ransohoff R.M. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 43 (1993) 2080-2087
53. Sato S., Fujimoto M., Hasegawa M., Komura K., Yanaba K., Hayakawa I., Matsushita T., and Takehara K. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology 43 (2004) 1261-1266
54. Schlotmann T., Waase I., Julch C., Klauenberg U., Muller-Myhok B., Dietrich M., Fleischer B., and Broker B.M. CD4alpha/beta T lymphocytes express high levels of the T lymphocyte antigen CTLA-4 (CD152) in acute malaria. J. Infect. Dis. 182 (2000) 367-370
55. Steiner K., Waase I., Rau T., Dietrich M., Fleischer B., and Broker B.M. Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection. Clin. Exp. Immunol. 115 (1999) 451-457
56. Teleshova N., Bao W., Kivisakk P., Ozenci V., Mustafa M., and Link H. Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment. Scand. J. Immunol. 51 (2000) 312-320
57. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., and Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative role of CTLA-4. Immunity 3 (1995) 541-547
58. Van Prijs L., and Abbas A.K. Homeostasis and self-tolerance in the immune system; turning lymphocyte off. Science 280 (1998) 243-248
59. Van Seventer G.A., Shimizu Y., Horgan K.J., and Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J. Immunol. 144 (1990) 4579-4586
60. Wang X.B., Kakoulidou M., Giscombe R., Qiu Q., Huang D.R., Pirskanen R., and Lefvert A.K. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of AT-rich gene sequence. J. Neuroimmunol. 130 (2002) 224-232
61. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., and Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270 (1995) 985-988
62. Weinberg A.D., Wegmann K.W., Funatake C., and Withman R.H. Blocking OX-OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 162 (1999) 1818-1826
63. Zamvill S., Nelson P., Trotter J., Mitchell D., Knobler R., Fritz R., Trotter J., and Steinman L. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and clinical demyelination. Nature 317 (1985) 355-358